INNOVATE

VATE

LISTED

NYSE

INNOVATE IS
WHO WE ARE

INNOVATE IS
WHAT WE DO

INNOVATE is a platform of best-in-class assets in 3 key areas of the new economy:

INFRASTRUCTURE

- DBM Global: Largest steel fabrication and erection company in the USA

LIFE SCIENCES

- R2 Technologies: the first and only device to employ Cryomodulation™ using PRECISION COOLING to address SOURCES of redness, benign lesions, inflammation and more
- MediBeacon: Developing the first real-time monitoring of kidney function, which has received “breakthrough device designation” from the FDA and is being developed to address a $7 billion[(1)] market

SPECTRUM

- HC2 Broadcasting: One of the largest broadcast station groups in the US, owning 2.3 billion MHz POPs of spectrum

(1) Based on studies from LifeSci Advisors (2019) and L.E.K. (2017) commissioned by MediBeacon

The INNOVATE Executive Team

AVIE GLAZER – CHAIRMAN OF THE BOARD

- Leads INNOVATE's strategic and philosophical direction
- Strong insider equity ownership having invested over $62 million(1)
- An owner of the Super Bowl champion Tampa Bay Buccaneers
- Co-Chairman of Manchester United – the world's most popular sports team with 1.1 billion followers

PAUL K. VOIGT– INTERIM CEO

- Appointed Interim CEO on July 25, 2023
- Extensive investment experience with the Company
- Served as Senior Managing Director of Investments at INNOVATE from 2014 – 2018 where he assisted with spearheading capital raising and transaction sourcing activities
- Served as Senior Managing Director of Investments at Lancer Capital since 2019
- Directs INNOVATE'S day-to-day operations while maintaining focus on driving consistent, profitable growth across all business segments

EXECUTIVE MANAGEMENT

- Michael J. Sena – Chief Financial Officer – Over 25 years of finance, mergers & acquisitions, accounting and control experience

(1) Excludes backstop commitment and private investment related to the announced 2024 Rights Offering

INFRASTRUCTURE

DBM GLOBAL

SCHUFF STEEL

GRAYWOLF INDUSTRIAL

BANKER STEEL company

DBM VIRCON

AITKEN

DBM Global

- The largest steel fabrication and erection company in the USA
- Approx. $1.1 billion of reported backlog and $1.2 billion of adjusted[(1)] backlog as of 12/31/23 (down from $1.8 billion of reported and adjusted[(1)] backlog as of 12/31/22)
- Continues to see sizable projects and opportunity in the market and its pipeline for 2025
- DBM's best in class management team has a proven long-term track record of executing complex projects
- DBM expanded its geographic reach to the East Coast in 2021 with its acquisition of Banker Steel, which provides full-service fabricated structural steel and erection services
- DBM's GrayWolf subsidiary provides services including industrial multi-discipline construction, modularization, steel fabrication, steel construction management, maintenance, repair, erection, and installation to a diverse range of end markets
- DBM Vircon is a construction technology company providing state of the art modeling, detailing and digital engineering for high-profile projects internationally

(1) Adjusted Backlog takes into consideration awarded, but not yet signed contracts and there are no assurances that these contracts will be entered into in the timeframe we anticipate or at all.

Select DBM Steel Fabrication & Erection Projects

SoFi Stadium, Los Angeles

Apple Headquarters

Hudson Yards, New York

Fort Benning Hospital

Cosmopolitan Resort & Casino

Phoenix Convention Center

DBM Financial Summary

(Amounts in $ millions)









(1) See Appendix for reconciliation of Non-GAAP to U.S. GAAP.

(2) Adjusted Backlog takes into consideration awarded, but not yet signed contracts and there are no assurances that these contracts will be entered into in the timeframe we anticipate or at all.

LIFE SCIENCES

PANSEND

R2 Technologies

MediBeacon

GENOVEL

TRIPLE RING technologies

Scaled Cell Solutions

Pansend Life Sciences, LLC

- **Pansend is INNOVATE's life sciences platform**
- **Pansend has investments in five life science companies: R2 Technologies, MediBeacon, Genovel Orthopedics, Triple Ring Technologies and Scaled Cell Solutions**
- **Pansend was founded by and is led by David A. Present, MD and Cherine Eldumiati Plumaker. Their outstanding leadership has produced a proven track record for developing and monetizing life science companies**
- **In 2018, Pansend sold BeneVir to Janssen Biotech (J&J) for up to $1 billion[(1)]. BeneVir's proprietary T-Stealth oncolytic virus platform develops oncolytic viruses used to infect and destroy cancer cells**
- **INNOVATE receives 75% of Pansend's economic distributions after receipt of INNOVATE's invested capital, plus a preferred hurdle rate**

(1) Subject to certain pre-determined milestones. There are no assurances that milestones will be achieved.

R2 Technologies

- Glacial® Rx, launched in 2021 by R2 Technologies, is the first and only device to employ Cryomodulation™ using PRECISION COOLING to address SOURCES of redness, benign lesions, inflammation and more
- Massive market opportunity: $22 billion[1] skin tone evening, lightening and brightening products global market
- Glacial® Rx was developed by Drs. Rox Anderson, Dieter Manstein and Henry Chan – world famous dermatologists at Harvard Medical School who have created numerous commercially successful aesthetic dermatological devices such as Laser Hair Removal, Fractional Lasers/Fraxel, and Coolsculpting
- Glacial® Rx was given the award for the Best Age-Spot Eraser by NewBeauty in 2022
- Glacial® Rx was given the silver Merit Award for Innovations[2] in 2022
- Glacial® Rx was named among top 7 trending "Non-Invasive Beauty Treatments" by Cosmopolitan[3] in 2022
- Glacial® Spa launched in China in the first quarter 2022.
- Glacial® fx launched in U.S., India, and Middle East in the second half of 2023
- Expanded global reach with market approval in Saudi Arabia in United Arab Emirates in 2023
- Strong patent portfolio: 115 issued patents & 42 patents pending

(1) Source: The Jarvis Report 2016 (R2-Commissioned) and "Revolution in Aesthetic Medicine" (11-21-2015)
(2) https://www.businesswire.com/news/home/20221114005136/en/Merit-Awards-Announces-Winners-of-2022-Healthcare-Awards
(3)https://www.cosmopolitan.com/style-beauty/beauty/a42004968/non-invasive-beauty-treatments/

How Glacial® Rx Compares:

	Glacial Rx	Laser	Facial
Feels good	✖		✖
Little to no downtime	✖		✖
No heat	✖		✖
Proven effective on age spots	✖	✖	
Uses Cryomodulation technology	✖		
Can be performed any time of the year	✖		✖
No smoky plume	✖		✖

Results are typical after a single treatment and one can expect to see the full benefit of Glacial Rx within 1 to 2 months and in some cases, even sooner

MediBeacon

- MediBeacon has developed the first real-time monitoring of kidney function which has received "breakthrough device designation" from the FDA and is being developed to address a $7 billion market[(1)]. According to the FDA, a "Breakthrough Device" like the Transdermal GFR Measurement System is a product that has the potential to be more effective at diagnosing a life threatening or irreversible debilitating disease or condition compared to the current standard of care
- Significant medical opinions exist that current diagnostic tests to measure kidney function are inaccurate, providing indirect measurements, and are not real-time. Accurate kidney measurement is critical for treating patients in the hospital with 20-40% of patients at risk for kidney failure in critical care settings
- MediBeacon's Transdermal GFR Measurement System includes a patented compound, *Lumitrace™* that is entirely eliminated by the kidneys. *Lumitrace™* fluorescence is detected by a sensor placed on the skin, analogous to pulse oximetry for oxygen saturation
- MediBeacon's technology platform is being developed for use in gastrointestinal, ocular, and surgical visualization markets. Gastrointestinal is a $1 billion market[(2)], ocular is a $200 million market[(3)] and surgical visualization is a $100 million market[(4)]
- The FDA accepted MediBeacon's Investigational Device Exemption (IDE) application and, on June 26, 2022, MediBeacon initiated its Transdermal GFR Measurement System FDA Pivotal Study, with final regulatory submission made on June 18, 2023 and met with FDA in Q1 2024 in order to work towards approval status
- The FDA accepted MediBeacon's IDE in Q1 2023 enabling start of U.S. reusable sensor study. Upgraded design to provide important usability, cost and performance benefits. Clinical study began in March 2023
- Strong patent portfolio: 198 granted global patents, 51 granted U.S. patents & 244 global pending applications

(1) Based on studies from LifeSci Advisors (2019) and L.E.K. (2017) commissioned by MediBeacon
(2) Based on Effimed Exploratory GI Market Research (2017) commissioned by MediBeacon
(3) Based on Medicare Plan B data from 2012-2017 combined with MediBeacon market assumptions
(4) Based on US Centers for Disease and Prevention (CDC) statistics, "Urologic Complications from Surgery" Washington University School of Medicine (2021) and MediBeacon market assumptions


GFR 100
mL/min/1.73 m²
130
120
110
100
90
80
70
0
2
4
6
8
Time from injection (hours)
ZOOM
SHOW LIST
1 hr: 07 min
Estimated measurement time remaining
Transdermal GFR
MediBeacon
MediBeacon

Other Pansend Investments

Triple Ring Technologies

- On November 30, 2023, the Company sold a portion of its ownership in Triple Ring and received $5.0 million in cash proceeds and shares of Scaled Cell valued at $0.9 million.
- After the sale, Pansend owns 1.9%(1)

Scaled Cell Solutions, Inc.

- Scaled Cell Solutions, Inc. is developing a vein-to-vein autologous cell therapy manufacturing system which would take a patient's own cells, modify them, and then inject them back into the patient to treat diseases.
- Pansend Owns 20.1%(1)

Genovel Orthopedics

- "Mini Knee" for early osteoarthritis of the knee & "Anatomical Knee" a novel total knee replacement that has been granted a US patent
- Invented by Dr. Peter Walker (creator of the original Total Knee) at NYU Department of Orthopedic Surgery
- Pansend owns 75.2%(1)

(1) On a fully diluted basis.

SPECTRUM

HC2 Broadcasting

HC2 Broadcasting

- One of the largest broadcast station groups in the US with 251 operating broadcast stations in over 100 markets – including 34 of the top 35 markets
- One of the largest owners of broadcast spectrum in the US with more than 2.3 billion MHz POPs of spectrum
- As cable TV "cord cutting" increases and the number of over-the-air (OTA) viewers continues to grow – HC2 Broadcasting has one of the largest OTA distribution platform in the US
- Broadcasting's stations carry approx. 1,700 channels with programming from over 60 diginets
- Rising demand for a national distribution platform by large content providers increases revenues and margins for HC2 Broadcasting
- ATSC 3.0 (Next Gen TV) technology creates additional revenue opportunities
- Entered into agreements with PBS stations to provide ATSC 3.0 "lighthousing" along with commercial joint ventures in datacasting and other areas
- Actively exploring 5G broadcasting opportunities in the U.S. and have filed an application with the Federal Communications Commission to convert an existing station to 5G broadcast in order to participate in Phase 2 proof of concept

HC2's stations caryy approx. 1,700 channels with programming from over 60 diginets

ADDITIONAL INNOVATE OPPORTUNITIES

INNOVATE - Additional Opportunities

Benevir

- **As part of INNOVATE's sale of Benevir to Janssen Biotech in 2018, $140 million will be paid to INNOVATE upon certain regulatory approvals in the US, EU & Japan and up to $370 million will be paid to INNOVATE if certain sales milestones are reached**(1)

Favorable Tax Position

- **U.S. consolidated group had approximately $179.2 million NOL carryforwards, of which $119.2 million are estimated to be utilizable in 2024 + $211.7 million of IRC Sec. 163(j) interest carryforwards as of 12/31/23, which is subject to change based on the filing of the 2023 tax return**

(1) There are no assurances that approvals and milestones will be achieved.

SUMMARY

"It's rare to uncover a single investment in the new economy that's best-in-class.

To find a company that has multiple best-in-class assets is extraordinary."

Avie Glazer

INNOVATE Chairman

APPENDIX

Q4 2023 QTD Financial Highlights

Revenue

($ millions)	4Q23	4Q22
Infrastructure	$ 353.8	$ 397.3
Life Sciences	1.5	1.3
Spectrum	5.7	10.7
Consolidated INNOVATE	**$ 361.0**	**$ 409.3**

Net income (loss) Attrib. to INNOVATE Corp. & Adjusted EBITDA

	4Q23		4Q22	
($ millions)	NI[1]	Adjusted EBITDA[2]	NI[1]	Adjusted EBITDA[2]
Infrastructure	$ 8.9	$ 30.0	$ 5.9	$ 32.7
Life Sciences	(6.2)	(7.1)	(4.3)	(4.5)
Spectrum	(5.4)	1.1	(2.8)	2.5
Non-Operating Corporate	(5.4)	(2.5)	(4.9)	(3.7)
Other & Eliminations	(1.2)	—	0.4	1.1
Consolidated INNOVATE	**$ (9.3)**	**$ 21.5**	**$ (5.7)**	**$ 28.1**

(1) Net income (loss) attributable to INNOVATE Corp.

(2) See slides 26 and 27 for reconciliation of Non-GAAP to U.S. GAAP.

(3) Adjusted Backlog takes into consideration awarded, but not yet signed contracts.

Consolidated Q4 Results

- Revenue decreased $48.3M or 11.8% driven by our Infrastructure segment, and, to a lesser extent, our Spectrum segment. The decline at our Infrastructure segment was driven by timing and size of projects, mostly from DBMG's commercial structural steel fabrication and erection business, which was partially offset by increases at the industrial maintenance and repair business and Banker Steel, while revenues at our Spectrum segment decreased primarily as a result of the termination of HC2 Network, Inc. ("Network") and its associated Azteca America network ("Azteca") content on December 31, 2022.
- Net Loss attributable to INNOVATE Corp. of $9.3M
- Adjusted EBITDA[2] decreased by $6.6M to $21.5M driven by our Infrastructure, Life Sciences, Spectrum and Other segments, which was partially offset by our Non-Operating corporate segment.

Infrastructure

- Net Income of $8.9M[1]
- Adjusted EBITDA[2] down $2.7M year-over-year driven by an increase in recurring SG&A expenses.
- Reported and adjusted[3] backlog of $1.1B and $1.2B, respectively, compared to reported and adjusted[3] backlog of $1.8B at December 31, 2022.

Life Sciences

- Revenue of $1.5M driven by R2, which is up $0.2M or 15.4%, primarily as a result of the launch of the Glacial fx system in the U.S. and an increase in Glacial Rx units sold in the U.S., which was partially offset by a change in product mix sold outside the U.S, as more Glacial Spa systems, which have a lower retail price per unit, were sold compared to Glacial Rx systems, which have a higher retail price per unit, as well as decrease in consumables sold outside the U.S.
- Adjusted EBITDA losses[2] up $2.6M year-over-year primarily due to higher equity method losses recognized from our investment in MediBeacon in the current period due to additional investments in MediBeacon resulting in previously suspended losses to be recognized as the investment's carrying amount was reduced to zero, which was partially offset by a decrease in SG&A expenses at R2, driven by a decrease in marketing costs and compensation expenses as a result of cost reduction initiatives.

Spectrum

- Net Loss of $5.4M[1]
- Adjusted EBITDA[2] down $1.4M year-over-year primarily due to a one-time benefit related to the termination of Azteca in the prior period, which was partially offset by a decrease in unrepeated SG&A expenses in the prior period.

Non-Operating Corporate

- Adjusted EBITDA losses[2] down $1.2M primarily driven by a decrease in compensation and legal expenses.

Other & Eliminations

- Adjusted EBITDA[2] down $1.1M driven by the elimination of equity method income from our investment in HMN, which was sold on March 6, 2023.

Current Credit Picture

($ millions)

Debt Summary[1]

($ millions)	Maturity	Dec-23	Dec-22
8.50% Senior Secured Notes	2026	$ 330.0	$ 330.0
7.50% Convertible Senior Notes	2026	51.8	51.8
Line of Credit	2025	20.0	20.0
CGIC Unsecured Note	2026	35.1	—
Infrastructure Debt	Various	198.8	243.0
Spectrum Debt	2025	69.7	69.7
Life Science Debt	2024	17.4	10.8
Total Principal Outstanding		**$ 722.8**	**$ 725.3**
Unamortized OID and DFC		(13.0)	(10.9)
Total Debt		**$ 709.8**	**$ 714.4**
Cash & Cash Equivalents[3]		80.8	80.4
Net Debt		**$ 629.0**	**$ 634.0**

Debt Amortization and Maturity Profile[2]



(1) Debt Maturity Profile excludes Preferred Stock and operating leases
(2) Debt Amortization and Maturity Profile chart presents debt annual amortization and maturity payments
(3) Excludes restricted cash

Reconciliation of U.S. GAAP Income (Loss) to Adjusted EBITDA

(in millions)

	Three Months Ended December 31, 2023					
	Infrastructure	Life Sciences	Spectrum	Non-Operating Corporate	Other and Eliminations	INNOVATE
Net income (loss) attributable to INNOVATE Corp.	$ 8.9	$ (6.2)	$ (5.4)	$ (5.4)	$ (1.2)	$ (9.3)
Adjustments to reconcile net income (loss) to Adjusted EBITDA:						
Depreciation and amortization	2.8	0.2	1.3	—	—	4.3
Depreciation and amortization (included in cost of revenue)	4.0	—	—	—	—	4.0
Other operating (income) loss	—	—	(0.2)	0.5	1.1	1.4
Interest expense	3.5	0.8	3.4	11.5	—	19.2
Other (income) expense, net	—	—	2.2	(1.8)	0.1	0.5
Income tax expense (benefit)	9.2	—	0.3	(8.2)	—	1.3
Non-controlling interest	0.9	(1.7)	(0.5)	—	—	(1.3)
Share-based compensation expense	—	(0.3)	—	0.5	—	0.2
Acquisition and disposition costs	0.7	0.1	—	0.4	—	1.2
Adjusted EBITDA	**$ 30.0**	**$ (7.1)**	**$ 1.1**	**$ (2.5)**	**$ —**	**$ 21.5**

Reconciliation of U.S. GAAP Income (Loss) to Adjusted EBITDA

(in millions)

	Three Months Ended December 31, 2022					
	Infrastructure	Life Sciences	Spectrum	Non-Operating Corporate	Other and Eliminations	INNOVATE
Net income (loss) attributable to INNOVATE Corp.	$ 5.9	$ (4.3)	$ (2.8)	$ (4.9)	$ 0.4	$ (5.7)
Adjustments to reconcile net income (loss) to Adjusted EBITDA:						
Depreciation and amortization	5.1	0.1	1.4	—	—	6.6
Depreciation and amortization (included in cost of revenue)	3.8	—	—	—	—	3.8
Interest expense	3.1	0.6	1.3	8.6	—	13.6
Other expense (income), net	0.9	0.8	2.1	(1.9)	(0.2)	1.7
Income tax expense (benefit)	5.1	—	(0.1)	(6.4)	0.7	(0.7)
Non-controlling interest	0.5	(1.9)	(0.4)	—	0.2	(1.6)
Share-based compensation expense	—	0.2	—	0.5	—	0.7
Restructuring and exit costs	6.4	—	0.7	—	—	7.1
Acquisition and disposition costs	1.9	—	0.3	0.4	—	2.6
Adjusted EBITDA	**$ 32.7**	**$ (4.5)**	**$ 2.5**	**$ (3.7)**	**$ 1.1**	**$ 28.1**

Reconciliation of U.S. GAAP Income (Loss) to Adjusted EBITDA

(in millions)	DBM Global (Infrastructure Segment) For the Year Ended December 31,				
	2019	**2020**	**2021**	**2022**	**2023**
Net Income attributable to INNOVATE Corp.	$ 24.7	$ 6.8	$ 16.9	$ 29.2	$ 28.7
Adjustments to reconcile net income to Adjusted EBITDA:					
Depreciation and amortization	15.5	10.7	19.1	21.0	14.4
Depreciation and amortization (included in cost of revenue)	9.1	9.1	12.2	15.0	15.7
Other operating loss (income)	0.5	0.1	0.4	(0.6)	(0.2)
Interest expense	9.3	8.5	8.5	10.1	13.8
Other (income) expense, net	(1.6)	0.5	(4.0)	(1.0)	(1.2)
Loss on early extinguishment or restructuring of debt	—	—	1.5	—	—
Income tax expense	10.9	4.2	10.5	16.5	20.2
Non-controlling interest	2.0	0.6	1.8	2.8	2.8
Legacy accounts receivable expense	—	—	—	—	2.2
Restructuring and exit costs	—	—	—	6.5	2.1
Nonrecurring Items	—	2.7	0.5	—	—
COVID-19 costs	—	19.4	8.6	—	—
Acquisition and disposition costs	5.3	0.6	2.4	2.2	2.1
Adjusted EBITDA	**$ 75.7**	**$ 63.2**	**$ 78.4**	**$ 101.7**	**$ 100.6**

INNOVATE

For more information email
ir@innovatecorp.com

or visit
www.innovatecorp.com

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This presentation contains, and certain oral statements made by our representatives from time to time may contain, "forward-looking statements." Generally, forward-looking statements include information describing actions, events, results, strategies and expectations and are generally identifiable by use of the words “believes,” “expects,” “intends,” “anticipates,” “plans,” “seeks,” “estimates,” “projects,” “may,” “will,” “could,” “might,” or “continues” or similar expressions. Such forward-looking statements are based on current expectations and inherently involve certain risks, assumptions and uncertainties. The forward-looking statements in this presentation include, without limitation, any statements regarding INNOVATE’s plans and expectations for future growth and ability to capitalize on potential opportunities, the achievement of INNOVATE’s strategic objectives, expectations for performance of new projects and realization of revenue from the backlog at DBM Global, anticipated success from the continued sale of new products in the Life Sciences segment, anticipated developments regarding the FDA approval process at MediBeacon, anticipated performance of new channels and LPTV frequencies, expanded uses for LPTV channels in the Spectrum segment and the deployment of datacasting, anticipated agreements in the Spectrum segment with public broadcast networks, anticipated 5G broadcasting opportunities in the Spectrum segment, anticipated developments regarding Federal Communications Commission approval to convert existing station to 5G broadcast, our intentions to regain compliance with the NYSE's continued listing standards, and changes in macroeconomic and market conditions and market volatility (including developments and volatility arising from the COVID-19 pandemic), including interest rates, the value of securities and other financial assets, and the impact of such changes and volatility on INNOVATE’s financial position. Such statements are based on the beliefs and assumptions of INNOVATE’s management and the management of INNOVATE’s subsidiaries and portfolio companies. The Company believes these judgments are reasonable, but you should understand that these statements are not guarantees of performance, results or the creation of stockholder value and the Company’s actual results could differ materially from those expressed or implied in the forward-looking statements due to a variety of important factors, both positive and negative, including those that may be identified in subsequent statements and reports filed with the Securities and Exchange Commission (“SEC”), including in our reports on Forms 10-K, 10-Q, and 8-K. Such important factors include, without limitation: our dependence on distributions from our subsidiaries to fund our operations and payments on our obligations; the impact on our business and financial condition of our substantial indebtedness and the significant additional indebtedness and other financing obligations we may incur; our dependence on key personnel; volatility in the trading price of our common stock; the impact of recent supply chain disruptions, labor shortages and increases in overall price levels, including in transportation costs; interest rate environment; developments relating to the ongoing hostilities in Ukraine and Israel; increased competition in the markets in which our operating segments conduct their businesses; our ability to successfully identify any strategic acquisitions or business opportunities; uncertain global economic conditions in the markets in which our operating segments conduct their businesses; changes in regulations and tax laws; covenant noncompliance risk; tax consequences associated with our acquisition, holding and disposition of target companies and assets; the ability of our operating segments to attract and retain customers; our expectations regarding the timing, extent and effectiveness of our cost reduction initiatives and management’s ability to moderate or control discretionary spending; our expectations and timing with respect to any strategic dispositions and sales of our operating subsidiaries, or businesses; the possibility of indemnification claims arising out of divestitures of businesses; and our possible inability to raise additional capital when needed or refinance our existing debt, on attractive terms, or at all. Although INNOVATE believes its expectations and assumptions regarding its future operating performance are reasonable, there can be no assurance that the expectations reflected herein will be achieved. These risks and other important factors discussed under the caption “Risk Factors” in our most recent Annual Report on Form 10-K filed with the SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. You should not place undue reliance on forward-looking statements. All forward-looking statements attributable to INNOVATE or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made, and unless legally required, INNOVATE undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Non-GAAP Financial Measures

In this earnings release supplement, INNOVATE refers to certain financial measures that are not presented in accordance with U.S. generally accepted accounting principles ("GAAP"), including Total Adjusted EBITDA (excluding discontinued operations, if applicable) and Adjusted EBITDA for its operating segments. In addition, other companies may define Adjusted EBITDA differently than we do, which could limit its usefulness.

Adjusted EBITDA

Management believes that Adjusted EBITDA provides investors with meaningful information for gaining an understanding of our results as it is frequently used by the financial community to provide insight into an organization's operating trends and facilitates comparisons between peer companies, since interest, taxes, depreciation, amortization and the other items listed in the definition of Adjusted EBITDA below can differ greatly between organizations as a result of differing capital structures and tax strategies. Adjusted EBITDA can also be a useful measure of a company's ability to service debt. While management believes that non-U.S. GAAP measurements are useful supplemental information, such adjusted results are not intended to replace our U.S. GAAP financial results. Using Adjusted EBITDA as a performance measure has inherent limitations as an analytical tool as compared to net income (loss) or other U.S. GAAP financial measures, as this non-GAAP measure excludes certain items, including items that are recurring in nature, which may be meaningful to investors. As a result of the exclusions, Adjusted EBITDA should not be considered in isolation and does not purport to be an alternative to net income (loss) or other U.S. GAAP financial measures as a measure of our operating performance.

The calculation of Adjusted EBITDA, as defined by us, consists of Net income (loss) attributable to INNOVATE Corp., excluding discontinued operations, if applicable; depreciation and amortization; other operating (income) loss, which is inclusive of (gain) loss on sale or disposal of assets, lease termination costs, asset impairment expense and FCC reimbursements; interest expense; other (income) expense, net; loss on early extinguishment or restructuring of debt; income tax expense (benefit); non-controlling interest; share-based compensation expense; legacy accounts receivable expense; restructuring and exit costs; non-recurring items; and acquisition and disposition costs.

Third Party Sources

Third party information presented in this presentation is based on sources we believe to be reliable; however, there can be no assurance information so presented will prove accurate in whole or in part.